Cardiac Management During Adjuvant Trastuzumab Therapy
Author Information
Author(s): Mackey J.R. MD, Clemons M. MB BS, Côté M.A. MD, Delgado D. MD MSc, Dent S. BSc MD, Paterson A. MD, Provencher L. MD MA, Sawyer M.B. BSc Phm MD, Verma S. MD MSEd
Hypothesis
What are the recommendations for cardiac management during adjuvant trastuzumab therapy?
Conclusion
Trastuzumab significantly reduces the risk of recurrence and death in HER2-positive early breast cancer, but careful cardiac management is essential due to potential cardiotoxicity.
Supporting Evidence
- Trastuzumab reduces the 3-year risk of recurrence by nearly half.
- Trastuzumab therapy was associated with a 33% reduction in the risk of death.
- Cardiac dysfunction was observed in women treated with trastuzumab and chemotherapy.
- The incidence of cardiac dysfunction was greatest among patients who received trastuzumab with anthracycline-based therapy.
- Monitoring protocols for cardiac effects were included in subsequent trastuzumab trials.
Takeaway
Trastuzumab helps women with a certain type of breast cancer live longer, but it can hurt their hearts, so doctors need to watch their heart health closely.
Methodology
The Canadian Trastuzumab Working Group reviewed data from major adjuvant trials and formulated recommendations for cardiac monitoring and management.
Potential Biases
Potential bias in the recommendations due to the funding source from Roche Canada.
Limitations
The recommendations may evolve as more data becomes available and experience with trastuzumab grows.
Participant Demographics
Women with HER2-positive early breast cancer.
Statistical Information
P-Value
p = 0.0115
Confidence Interval
95% confidence interval (CI): 0.47 to 0.91
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website